◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › PBM

Psyence Biomedical Ltd. (PBM) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-09

Psyence Biomedical Ltd. (PBM) operates in the Biotechnology industry and is headquartered in Toronto, Canada with about 12 employees. Its market capitalization is roughly $11 million. In the fiscal year ended 2026-03-31, PBM reported $0M in revenue and ($7M) in net income.

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context.

Interactive charts & full statements →

PBM Revenue & Earnings History — Annual Income Statement

Income statement2026-03-312025-03-312024-03-312023-03-312022-03-31
Total Revenue$0M$0M$0M$0M
Operating Income (EBIT)($6M)($4M)($43M)($3M)
Net Income($7M)$1M($51M)($3M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PBM Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2025-09-30
Total Revenue$0M
Operating Income (EBIT)($2M)
Net Income($1M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PBM Free Cash Flow History

PBM Balance Sheet History

Balance sheet2026-03-312025-03-312024-03-312023-03-312022-03-31
Total Assets$18M$7M$1M$2M
Total Liabilities$1M$1M$12M$2M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PBM viewer.

Other Companies in Biotechnology

← PBLSAll stocksPBR →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.